Sintx Technologies, Inc. (SINT) · Oct 9, 2026 · Share issuance
$2.0M warrant exercise — $2.01M raised; 941,423 exercised and 941,423 expired
SINTX’s warrant exercise brings in $2.0M as it commercializes silicon-nitride medical products, but only half the called warrants were funded.
SINTX is moving from an advanced-materials developer toward commercializing silicon-nitride medical products, including its FDA-cleared SiNAPTIC Foot & Ankle Implant System, while also pursuing industrial and broader biomaterials applications.
The financing adds useful capital, but it is not a full cleanup of the warrant overhang. The company received $2.01 million of gross proceeds from funded exercises and exchanges at $2.14 per share, issuing common stock or fully pre-funded warrants because of 9.99% ownership limits.
| Filing item | Result |
|---|---|
| Gross proceeds | $2,014,645.22 (Warrant exercise update) |
| Class B warrant shares funded | 941,423 at $2.14 (Warrant exercise update) |
| Common shares issued | 651,204 (Warrant exercise update) |
| Pre-funded warrant shares | 290,219 (Warrant exercise update) |
| Class B warrant shares not exercised | 941,423, expired without consideration (Warrant exercise update) |
The key mixed signal is the 50% exercise rate. Exactly as many Class B warrant shares expired as were funded, meaning SINTX captured roughly half of the capital available under the called warrants rather than converting the entire block into cash. 〔0〕 That limits both the near-term funding benefit and the future dilution associated with those unexercised warrants.
The capital helps the commercialization push, but does not change the operating story. SINTX now has additional cash to support its medical-device rollout and materials platform, but this filing provides no new customer, revenue, regulatory, or execution milestone. The call itself was already announced on October 1, 2026, so the genuinely new information is the take-up rate and final capital raised, not the existence of the financing.
Bottom line: SINTX gets a modest funding boost and eliminates the remaining Class B warrant overhang, but only half the called warrants converted. The event supports the commercialization effort without materially changing the underlying business trajectory.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!